Status:

COMPLETED

Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus

Lead Sponsor:

Hecheng Li M.D., Ph.D

Conditions:

Esophageal Squamous Cell Carcinoma

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

Brief Summary

This study will evaluate the safety and feasibility of preoperative immune checkpoint therapy with concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. An...

Detailed Description

Esophageal cancer ranks the eighth most common cancer (the fifth most common cancer in China), while ESCC is the most common subtype in Asia (more than 90 % in china). Radical resection is thought to ...

Eligibility Criteria

Inclusion

  • A patient will be eligible for inclusion in this study only if ALL of the following criteria apply:
  • Histologically confirmed cT2-T4a,N0-N+,M0 resectable esophageal squamous cell carcinoma
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Patients approve and sign the informed consent

Exclusion

  • 1\. Patients with active autoimmune disease or history of autoimmune disease 2. Patients who have a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications 3. Subjects with a history of symptomatic interstitial lung disease 4. History of allergy to study drug components 5. Women must not be pregnant or breast-feeding 6. Men with female partners (WOCBP) that are not willing to use contraception 7. Patient has received prior chemotherapy, radiotherapy, target therapy and immune therapy for this malignancy or for any other past malignancy 8. Underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events

Key Trial Info

Start Date :

January 21 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 17 2020

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT03792347

Start Date

January 21 2019

End Date

June 17 2020

Last Update

November 22 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Ruijin Hospital, Shanghai JiaoTong University School of Medicine

Shanghai, Shanghai Municipality, China, 200025